AccurEdit Therapeutics' ART001 Becomes First Gene Editing Therapy in China to Achieve FDA RMAT Designation AccurEdit Therapeutics announced ART001, China's first gene editing therapy, received FDA RMAT designation, expediting its clinical development.

AccurEdit Therapeutics' ART001 Becomes First Gene Editing Therapy in China to Achieve FDA RMAT Designation #China #Suzhou #AccurEdit #ART001 #FDA_RMAT